DAFNA Capital Management LLC Buys 661,979 Shares of ProQR Therapeutics (NASDAQ:PRQR)

DAFNA Capital Management LLC raised its position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 73.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,567,561 shares of the biopharmaceutical company's stock after buying an additional 661,979 shares during the period. ProQR Therapeutics makes up about 1.1% of DAFNA Capital Management LLC's holdings, making the stock its 24th biggest holding. DAFNA Capital Management LLC owned approximately 1.92% of ProQR Therapeutics worth $4,154,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of PRQR. Jane Street Group LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $30,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $32,000. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at about $40,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at $54,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the company. Cantor Fitzgerald started coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. Evercore ISI started coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price target for the company. HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. Finally, Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.75.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, reaching $1.59. The stock had a trading volume of 256,306 shares, compared to its average volume of 618,726. The stock's 50-day simple moving average is $1.49 and its 200-day simple moving average is $2.38. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62. The firm has a market capitalization of $166.76 million, a PE ratio of -4.95 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.90 million. On average, research analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).